Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Hultafors Group AB in connection with the acquisition of Fristads, Kansas and Leijona
Mandate

Vinge advises Hultafors Group AB in connection with the acquisition of Fristads, Kansas and Leijona

May 12, 2021 M&A

The acquisition of Fristads, Kansas and Leijona is part of Hultafors Group’s strategy for growth and development of leading trademarks within the personal security equipment segment in Europe and North America.

Hultafors Group’s products, which include, among other things, protective clothing and protective equipment, are sold to professional users.

The acquisition was completed in March 2021 and Vinge’s team was headed by advokat Wibeke Sorling,  advokat and partner Anna Palmérus, advokat Petronella Hallberg, associate Jenny Sandlund, advokat Alexander Lindeberg as well as associates Victoria Gunnerek, Hanna Marberg and Jacob Benzow.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024